Stablecoin Development Corp (SDEV) Stock

Stablecoin Development Corp (SDEV) is a Healthcare stock trading at $1.15 (as of 2026-08-21), with a market capitalization of $58.21M and a trailing P/E of 0.1. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Understand Stablecoin Development Corp: how it makes money

Stablecoin Development Corp is a company classified in the healthcare sector (pharmaceutical products), focused on stablecoin-related development based on its name. The provided facts do not describe how it makes money.

The provided materials show reported profitability (operating margin) but no disclosed revenue breakdown by business segment and no operating KPIs, so the underlying profit drivers are not observable from the given facts.

Business quality (Exceptional): Investor insight is constrained by missing core inputs (no business description, no segment breakdown, no operating KPIs). The latest quarter shows revenue of 0.0B and an operating margin of 905.0, but the context needed to interpret profit drivers is not provided.

Valuation: At 0× earnings, SDEV trades 98% below the Pharmaceutical Products average (17×). Note: one-time items can distort reported P/E.

Bull case

  • Strong reported operating margin: For the period ending 2026-03-31, the reported operating margin is 905.0.

Bear case

  • No observable revenue or business drivers in the provided data: The provided facts show revenue of 0.0B and include no segment revenue candidates or operating KPI candidates, limiting the ability to understand what drives results.
  • Profitability signal may lack context: The operating margin figure (905.0) is difficult to interpret without additional disclosure, such as gross margin, segment mix, or operating performance metrics.
Valuation — source: SEC EDGAR (first-party)
Price$1.15
Market Cap$58.21M
P/E Ratio0.1
Price / Book0.46
Price / Sales7.61
FCF Yield-10.6%
DCF Value (model)$2.35
DCF Upside vs Price104.3%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$9.78M
Net Margin-73.8%
Revenue Growth (YoY)-33.6%
EPS Growth (YoY)-36.1%
FCF Growth (YoY)80.8%
Valuation vs Sector & Industry
Stock P/E0.1
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.0
vs Sector-99.7%
vs Industry-99.7%
Company
SectorHealthcare
IndustryPharmaceutical Products

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Lixte Biotechnology Holdings, Inc. (LIXT)
  • Heron Therapeutics, Inc. (HRTX)
  • Talphera, Inc. (TLPH)
  • RenovoRx, Inc. (RNXT)
  • Clene Inc. (CLNN)
  • Context Therapeutics Inc. (CNTX)
  • Xilio Therapeutics, Inc. (XLO)
  • Impact BioMedical Inc. (IBO)
SDEV earnings history · SDEV institutional & insider holders · SDEV KPIs & operating metrics · SDEV financials · SDEV investor presentations & press releases · SDEV SEC filings · SDEV peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.